NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Adlai Nortye Group Ltd. (ANL) Stock Analysis

Adlai Nortye Group Ltd. (ANL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ANL

$11.26

+$0.62 (+5.83%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANL with… →

ANL Key Statistics

As of Oct 21, 2026
Trading
Open
$10.80
Previous Close
$10.64
Day's Range
10.80–11.68
52-Week Range
0.88–17.25
Volume
532.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.11
Valuation
Market Cap
$725.12M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
40.16
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.66
Financials (FY)
Revenue (FY)
$5.00M
Net Income (FY)
−$35.53M
Profit marginThe share of revenue left as profit after all costs and taxes.
−124.77%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
58.73M
1-Year Return
+580.36%
Dividend and dates
Avg Volume
211.20K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ANL closed at $11.26, +580.36% over 1 year.

Adlai Nortye Group Ltd. (ANL) has a market capitalization of $725.12M.

In fiscal 2025, ANL reported revenue of $5.00M.

ANL Stock Return by Calendar Year

Adlai Nortye Group Ltd. (ANL) return since Sep 2023: what $10,000 became

1 year
$10,000 $68,036
+580.36%
3 years
$10,000 $12,173
+21.73%
Since Sep 2023
$10,000 $7,507
−24.93%

If you had invested $10,000 in Adlai Nortye Group Ltd. (ANL) at the close on September 29, 2023, the earliest close on record here, it would have been worth $7,507 at the close on October 21, 2026: −24.93% in total, −8.94% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+692.96%
2025−47.11%
2024−70.13%
2023 (partial year)−40.07%

As of October 21, 2026.

ANL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$5.00M−$35.53M−710.6%
2024$0.00−$51.87M—
2023$0.00−$109.23M—
2022$0.00−$58.79M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$5.00M—−$35.70M−$35.53M−710.6%
2024$0.00—−$52.93M−$51.87M—
2023$0.00—−$72.55M−$109.23M—
2022$0.00—−$67.27M−$58.79M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ANL Valuation vs Biotechnology Median

Median of 608 stocks
MetricANLBiotechnology medianvs median
P/S ratio40.1613.303.0x the median
Profit margin−124.77%−38.31%86.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Adlai Nortye Group Ltd. (ANL) at $725.12M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 109.

The 52-week range on file runs from $0.88 to $17.25. The most recent close on file for ANL is $11.26, dated October 21, 2026. That is +$0.62 (+5.83%) against the previous close. The latest close sits 1,181% above that 52-week low.

Financial Health

In fiscal 2025, Adlai Nortye Group Ltd. reported revenue of $5.00M. The same year closed with a net loss of $35.53M. Profit margin runs at −124.77%. That is 86.5 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −0.66.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $5.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 40.16 times revenue. On price-to-sales that is 3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.11. Daily returns over the trailing 3 years annualize to a volatility of 117.9%. The trailing one-year total return is +580.36%. Measured over 3 years, that is +6.77% a year compounded.

Growth & Income

The record shows no dividend for ANL.

The strongest complete calendar year on file is 2025 at −47.11%; the weakest is 2024 at −70.13%. So far in 2026 the total return is +692.96%.

Peer Comparison

Adlai Nortye Group Ltd. (ANL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Adlai Nortye Group Ltd. ANL $725.12M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Adlai Nortye Group Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Visit website →